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Screen-readingAbstract Purpose: We compared detection measures for breast screening strategies
comprising single-reading or double-reading using standard 2D-mammography or 2D/3D-
mammography, based on the ‘screening with tomosynthesis or standard mammography’
(STORM) trial.
Methods: STORM prospectively examined screen-reading in two sequential phases, 2D-
mammography alone and integrated 2D/3D-mammography, in asymptomatic women partic-
ipating in Trento and Verona (Northern Italy) population-based screening services. Outcomes
were ascertained from assessment and/or excision histology or follow-up. For each screen-
reading strategy we calculated the number of detected and non-detected (including interval)
cancers, cancer detection rates (CDRs), false positive recall (FPR) measures and incremental
CDR relative to a comparator strategy. We estimated the false:true positive (FP:TP) ratio and
sensitivity of each mammography screening strategy. Paired binary data were compared using
McNemar’s test.
Results: Amongst 7292 screening participants, there were 65 (including six interval) breast
cancers; estimated ﬁrst-year interval cancer rate was 0.82/1000 screens (95% conﬁdence
interval (CI): 0.30–1.79/1000). For single-reading, 35 cancers were detected at both 2D andel.: +61
1800 N. Houssami et al. / European Journal of Cancer 50 (2014) 1799–18072D/3D-mammography, 20 cancers were detected only with 2D/3D-mammography compared
with none at 2D-mammography alone (p < 0.001) and 10 cancers were not detected. For dou-
ble-reading, 39 cancers were detected at 2D-mammography and 2D/3D-mammography, 20
were detected only with 2D/3D-mammography compared with none detected at 2D-mam-
mography alone (p < 0.001) and six cancers were not detected. The incremental CDR attrib-
utable to 2D/3D-mammography (versus 2D-mammography) of 2.7/1000 screens (95% CI:
1.6–4.2) was evident for single and for double-reading. Incremental CDR attributable to dou-
ble-reading (versus single-reading) of 0.55/1000 screens (95% CI: 0.02–1.4) was evident for
2D-mammography and for 2D/3D-mammography. Estimated FP:TP ratios showed that
2D/3D-mammography screening strategies had more favourable FP to TP trade-off and
higher sensitivity, applying single-reading or double-reading, relative to 2D-mammography
screening.
Conclusion: The evidence we report warrants rethinking of breast screening strategies and
should be used to inform future evaluations of 2D/3D-mammography that assess whether
or not the estimated incremental detection translates into improved screening outcomes such
as a reduction in interval cancer rates.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Mammography screening has been shown to
reduce breast cancer mortality in overviews of the
randomised trials, and both its beneﬁts and harms
have been evaluated and debated [1–3]. Recently,
two prospective population-based screening trials
[4,5] have shown that adding digital breast
tomosynthesis or 3D-mammography, a derivative
mammographic technology [6–9], to conventional
2D-mammography signiﬁcantly increases breast can-
cer detection. Both of these landmark studies have
also shown that the addition of 3D-mammography
can also reduce false recalls [4,5], although the extent
that it could reduce false recalls varies according to
the screen-reading and recall strategy, and may be
more evident in screening settings where false recalls
are relatively more frequent [10–12]. Given that inter-
national variations exist with regard to screen-reading
strategies, speciﬁcally whether single-reading or dou-
ble-reading is used, and the emerging data on 3D-
mammography for population screening, evidence on
the comparative contribution of various screening
strategies to detection measures will be critical in
guiding future breast screening research, practice
and policy.
In this study, we examine the eﬀect of various
screen-reading strategies on cancer detection and
false recall measures, based on the ‘screening
with tomosynthesis or standard mammography’
(STORM) trial [4]. We compare mammography
screening strategies comprising single-reading or
double-reading using standard 2D-mammography
or using integrated 2D/3D-mammography for popu-
lation screening, in terms of cancer detection and
false recalls.2. Methods
2.1. Screening setting and participants
This study is based on the prospective population-based
STORM [4] screening study which compared two sequen-
tial mammography screen-readings, 2D-mammography
alone and integrated 2D/3D-mammography whereby
3D-mammography is reported with the availability of
2D-mammography.TheSTORMstudymethods andpop-
ulation, and initial results, have been reported by Ciatto
and colleagues [4], and are described brieﬂy in the present
paper. STORM recruited asymptomatic women aged
P48 years through twoNorth Italian services that provide
biennial population breast screening in Trento and Vero-
na, August 2011 to June 2012 [4]. Screening participants
were invited to have integrated 2D/3D mammography
screening, and those opting not to participate in the study
had (standard) 2D-mammography [4]. The study was
granted institutional ethics approval, and informed con-
sent was obtained from participants [4].
Screening participants in STORM had digital mam-
mography using a Selenia Dimensions Unit with inte-
grated 2D/3D mammography performed as the
COMBO procedure (Hologic, Inc., Bedford, MA, Uni-
ted States of America (USA)): 2D and 3D images were
acquired with a single breast positioning and compres-
sion, with each of the 2D and 3D acquisitions comprising
bilateral two-view (cranio-caudal and mediolateral obli-
que) mammography.
2.2. Screen-reading
Screening mammograms were interpreted sequentially
by radiologists initially using standard 2D-mammogra-
phy alone, and were then re-interpreted by the same
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the same screen-reading session [4]. Integrated 2D/3D
mammography therefore refers to screen-reading based
on interpretation of 3D-mammography with availability
of the 2D-mammograms. Radiologists were required to
report whether or not to recall at each screen-reading
phase: 2D-mammograms were reported before progress-
ing to integrated 2D/3D mammography screen-reading.
Eight dedicated breast radiologists participated in
screen-reading (median 1791 screen-reads, range 1315–
2370); they were experienced in screening mammogra-
phy, and had received training in 3D-mammography
and had used it in assessment (approximately 6–
12 months) before participating in STORM. We have
recently reported reader-speciﬁc detection measures for
the STORM trial [13].
Independent double-reading was performed in accord
with the standard practice in European breast screening
services [4,14,15]. Screening participants were recalled
for further assessment based on a positive screen from
recall by either screen-reader at either 2D or 2D/3D
mammography reporting; hence discordant reads were
recalled to assessment.
2.3. Modelling screen-reading strategies
We investigated mammography screen-reading strat-
egies (Table 1) comprising single-reading with standard
2D-mammography, single-reading with integrated 2D/
3D-mammography, double-reading with 2D-mammog-
raphy, and double-reading with integrated 2D/3D-
mammography. Our primary analyses compared the
eﬀect of integrated 2D/3D-mammography, relative to
2D-mammography, on detection measures (for single-
reading and for double-reading). Secondary analyses
examined the eﬀect of double-reading relative to
single-reading for each mammography method, and
compared integrated 2D/3D-mammography (single-
reading) to 2D-mammography (double-reading)
because the latter is a frequently applied strategy inTable 1
Breast cancer detection for diﬀerent mammography screen-reading strateg
Breast cancer detection
Single-reading
Mammogram 2D/3D positive 2D/3D negative Total
2D positive 35 0 35
2D negative 20 10 30
Total 55 10 65
**p < 0.001
* STORM (screening with tomosynthesis or standard mammography trial):
women at screening and six interval cancers – data diﬀer from those reported
cancers.
 Comprises four cancers (detected through double-reading) that were not
follow-up).
** Exact p-value for Mc Nemar’s test for paired binary data.population-based screening programs. Because the
STORM trial used double-reading, the single-reading
strategy was modelled using the ﬁrst read performed
for each screening examination, as this inherently rep-
resents the most independent screen-read. The models
examined false recalls based on the recall rules applied
in STORM, as well as conditional recall whereby
integrated 2D/3D-mammography positivity was a con-
dition to recall (and screening recalled at 2D-mammog-
raphy only would not be recalled) [4].
2.4. Statistical analysis and outcome measures
The statistical planning of STORM has been detailed
in our previous work, and sample estimates factored that
the majority of screens in the participating centres repre-
sented incident screening [4]. The STORM study was
powered for comparison of cancer detection as the pri-
mary end-point [4]. For the present analysis, outcome
measures included the number of cancers detected, and
the cancer detection rate (CDR) per 1000 screens, for
each screening strategy, and the number and percentage
of false positive recall (FPR). We estimated the incremen-
tal CDR attributable to using a modiﬁed screen-reading
strategy relative to a baseline strategy (for example, the
incremental CDR from using integrated 2D/3D relative
to 2D-mammography). To elucidate the potential eﬀect
of 2D/3D-mammography screening on FPR, we exam-
ined the overall FPR, the proportion of FPR contributed
exclusively by 2D-mammography or by 2D/3D-mam-
mography (or by both), and conditional FPR as deﬁned
above. We calculated exact (Clopper–Pearson) 95% con-
ﬁdence intervals (95% CIs) for CDR and for all propor-
tions. McNemar’s test was used to test for diﬀerence in
paired proportions. All of these analyses were conducted
using SAS [16]. StatsDirect [17] was used to compute an
exact 95% CI for incremental CDR.
We estimated the false-positive to true-positive
(FP:TP) ratio for six potential screening strategies
represented in our data: this ratio expresses the numberies (based on the STORM study*).
Double-reading
Mammogram 2D/3D positive 2D/3D negative Total
2D positive 39 0 39
2D negative 20 6 26
Total 59 6 65
**p < 0.001
65 breast cancers in study population include 59 cancers detected in 57
by Ciatto et al. [4] because we included follow-up for ﬁrst-year interval
detected using single-reading plus six interval cancers (based on 1-year
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hence lower ratios represent more eﬀective (more accu-
rate) strategies. Since the FP:TP ratio is equivalent to
an odds, exact logistic regression was used to estimate
the 95% CI using SAS.
Outcomes were ascertained on the basis of excision
histology in those who received surgery, or based on
the completed assessment outcome (work-up imaging
and needle biopsy) in recalled subjects, and a minimum
follow-up of 13 months to identify ﬁrst-year interval
cancers (cancers diagnosed after a negative mammo-
graphic screen and before the next scheduled screen).
Therefore all data reported in this study will diﬀer from
our initial report of STORM because we included ﬁrst-
year interval cancers in the present analyses. Interval
cancers were identiﬁed using unique record numbers
for imaging episodes that are checked against local hos-
pital and pathology databases, which, in the local con-
text, provides timely notiﬁcation of interval cancers to
breast screening services. On this basis, our sensitivity
data represent comparative sensitivity of the mammo-
graphic strategies at 1-year follow-up and does not rep-
resent program sensitivity, because we did not have data
on interval cancers for the second year of the inter-
screening interval.
2.5. Role of funding source
The funding sources did not have any role in the
design of the study, in the collection, analysis, or inter-
pretation of the data, in the writing of the report or in
the decision to submit the paper.
3. Results
There were 7292 screening participants (median age
58 years): 59 breast cancers were detected at screening
in 57 subjects (two with bilateral cancer are therefore
double-counted) comprising 52 invasive cancers and
seven ductal carcinoma in situ (DCIS). Cancer charac-
teristics have been described in our initial report of
STORM [4], and further details of tumour characteris-
tics, by detection method, are included as online-only
Appendix. At a median follow-up of 19.7 months
(inter-quartile range 16.9–22.0 months), allowing ascer-
tainment only for ﬁrst-year interval cancers, there were
six interval cancers, and one false-negative assessment
which had been recommended for early re-screen. The
latter has been excluded from further analysis due to
the problem of classifying this screen which was recalled
(hence screen-positive) at both 2D-mammography and
2D/3D-mammography. The estimated ﬁrst-year interval
cancer rate was 0.82/1000 screens (95% CI: 0.30–1.79/
1000).
Tables 1 and 2 report cancer detection results; cross-
tabulated data (Table 1) show that for the single-readingstrategy, of 65 cancers, 35 were detected at both 2D and
2D/3D-mammography, 20 cancers were detected only
with integrated 2D/3D-mammography compared with
none detected at 2D-mammography alone (p < 0.001)
and 10 cancers were not detected. For double-reading,
of 65 cancers, 39 were detected at both 2D and 2D/
3D-mammography, 20 cancers were detected only with
integrated 2D/3D-mammography compared with none
detected at 2D-mammography alone (p < 0.001) and
six cancers were not detected. The corresponding CDRs,
summarised in Table 2, show an estimated incremental
CDR of 2.7/1000 screens (95% CI: 1.6–4.2) for
integrated 2D/3D-mammography versus 2D-mammog-
raphy (p < 0.001) whether single-reading or double-
reading is applied. An incremental CDR of 0.55/1000
screens (95% CI: 0.02–1.4) was achieved with double-
reading versus single-reading (p = 0.13) for each of
2D-mammography and 2D/3D-mammography. An
incremental CDR of 2.2/1000 screens (95% CI: 1.0–
3.6) was estimated for integrated 2D/3D-mammography
(with single-reading) compared to a strategy of 2D-
mammography screening (with double-reading). At
double-reading (and excluding interval cancers as these
were not recalled by either reader), the proportion of
discordant reads for cancers was similar for both
screen-reading methods: there were 8 of 39 (21%) discor-
dant reads for 2D-mammography and 14 of 59 (24%)
discordant reads for integrated 2D/3D-mammography.
FPR data are shown in Tables 3 and 4. A single-read-
ing strategy would have resulted in 328 FPRs (4.5% of
screens; 95% CI: 4.1–5.0) based on the study protocol:
148 FPRs at both screen-readings, 124 FPRs at 2D-
mammography only compared with 56 FPRs at 2D/
3D-mammography (p < 0.001). Single-reading with con-
ditional recall would have resulted in FPR in 2.8% of
screens (95% CI: 2.5–3.2). Double-reading resulted in
394 FPRs (5.5% of screens; 95% CI: 4.9–6.0): 180 FPRs
at both screen-readings, 141 FPRs at 2D-mammogra-
phy only compared with 73 FPRs at 2D/3D-mammog-
raphy (p < 0.001). Double-reading with conditional
recall would have resulted in FPR in 3.5% of screens
(95% CI: 3.1–4.0). FPR based on the study protocol,
the contribution to FPR from each of 2D or 2D/3D
screen-reading or both, and the estimated FPR condi-
tional to integrated 2D/3D-mammography positivity,
are shown in Table 4.
Table 5 summarises the FP:TP ratio for screening
strategies, ranked from the lowest to highest ratio (most
to least eﬀective FP:TP trade-oﬀ), and the corresponding
recall rate and sensitivity for each strategy. Strategies
using integrated 2D/3D-mammography (with condi-
tional recall), whether single-reading or double-reading,
provide the lowest (most eﬀective) FP:TP ratio and had
high sensitivities, although double-reading had the high-
est sensitivity (Table 5). 2D-mammography screening,
whether applying single-reading or double-reading,
Table 2
Comparison of breast cancer detection rates for diﬀerent screening strategies (based on the screening with tomosynthesis or standard
mammography (STORM) study [4]).
Screening strategy (mammography
modality and screen-reading method)
Number of
cancers detected
Cancer detection rate (CDR) per1000




Primary outcome: Eﬀect of integrated 2D/3D-mammography relative to 2D-mammography by reading strategy
2D-mammography, single-reading 35 4.8 (3.3, 6.7) – –
Integrated 2D/3D-mammography, single-
reading
55 7.5 (5.7, 9.8) 2.7 (1.6, 4.2) p < 0.001
2D-mammography, double-reading 39 5.3 (3.8, 7.3) – –
Integrated 2D/3D-mammography, double-
reading
59 8.1 (6.2, 10.4) 2.7 (1.6, 4.2) p < 0.001
Secondary outcome: Eﬀect of double-reading relative to single-reading for each mammography modality
2D-mammography, single-reading 35 4.8 (3.3, 6.7) – –
2D-mammography, double-reading 39 5.3 (3.8, 7.3) 0.55 (0.02, 1.4) p = 0.13
Integrated 2D/3D-mammography, single-
reading
55 7.5 (5.7, 9.8) – –
Integrated 2D/3D-mammography, double-
reading
59 8.1 (6.2, 10.4) 0.55 (0.02, 1.4) p = 0.13
Secondary outcome: Comparison of 2D/3D-mammography with single-reading and 2D-mammography with double-reading
2D-mammography, double-reading 39 5.3 (3.8, 7.3)
Integrated 2D/3D-mammography, single-
reading
55 7.5 (5.7, 9.8) 2.2 (1.0, 3.6) p < 0.001
 p-Value for Mc Nemar’s test for paired binary data.
Table 3
Screens classiﬁed as not having breast cancer, inclusive of false positive recall (FPR), for diﬀerent screening strategies (based on the STORM
study*).
No breast cancer (includes FPR)
Single-reading Double-reading
Mammogram 2D/3D positive 2D/3D negative Total Mammogram 2D/3D positive 2D/3D negative Total
2D positive 148 124 272 2D positive 180 141 321
2D negative 56 6900 6956 2D negative 73 6834 6907
Total 204 7024 7228 Total 253 6975 7228
**p < 0.001 **p < 0.001
* STORM: screening with tomosynthesis or standard mammography trial, data are updated from Ciatto et al. [4] to reﬂect follow-up for interval
cancers hence total screens classiﬁed as not having cancer diﬀers from our previous report (see Section 2).
** Exact p-value for Mc Nemar’s test for paired binary data.
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each detected cancer) and the lowest sensitivity amongst
the evaluated breast screening strategies.
4. Discussion
Population breast screening with mammography
may be at a crossroads; it is likely that clinicians,
public health policy makers and also women, will
contemplate decisions about 3D-mammography
(breast tomosynthesis) screening in the near future.
Two prospective screening trials embedded in popula-
tion-based programs have shown that screen-reading
using integrated 2D/3D-mammography (mammogra-
phy with tomosynthesis acquisitions) signiﬁcantly
increases CDR and can reduce false recalls. The latteris partly dependent on the recall rules, and appears
more substantial in retrospective evaluations [10,12]
than shown in the prospective trials. The emerging
evidence on 2D/3D-mammography screening and the
existing international variations in screen-reading
strategies (single or double-reading) necessitates
rethinking of mammography screening strategies with
a view to identifying the most eﬀective and eﬃcient
approach. We present a timely evaluation of the evi-
dence on detection measures for various mammogra-
phy screen-reading strategies based on the STORM
[4] trial, including the trade-oﬀ between cancer detec-
tion and false recalls. This evidence can guide screen-
ing practice and policy-making, and importantly it
can inform the planning of future breast screening
research and trials.
Table 4
False positive recall (FPR) for mammography screening, the contribution to FPR from 2D or 2D/3D-mammography based on single or double-
reading, estimated for study recall protocol and for conditional* recall (N = 7228).
Screening strategy (by mammography and screen-reading methods) No. of FPR FPR% (95% conﬁdence interval (CI))
Single-reading
Overall, recalled at either 2D or 2D/3D (study protocol) 328 4.5% (4.1–5.0)
Recalled at both 2D and 2D/3D mammography 148 2.0% (1.7–2.4)
Recalled at 2D mammography only 124 1.7% (1.4–2.0)
Recalled at 2D/3D mammography only 56 0.8% (0.6–1.0)
Conditional FPR* (recall using 2D/3D positivity as a condition) 204 2.8% (2.5–3.2)
Double-reading
Overall, recalled at either 2D or 2D/3D (study protocol) 394 5.5% (4.9–6.0)
Recalled at both 2D and 2D/3D mammography 180 2.5% (2.1–2.9)
Recalled at 2D mammography only 141 2.0% (1.6–2.3)
Recalled at 2D/3D mammography only 73 1.0% (0.8–1.3)
Conditional FPR* (recall using 2D/3D positivity as a condition) 253 3.5% (3.1–4.0)
* Conditional FPR estimates the FPR using integrated 2D/3D-mammography positivity as a condition to recall (meaning that screens recalled at
2D-mammography only would not be recalled).
 Total screens classiﬁed as not having breast cancer.
1804 N. Houssami et al. / European Journal of Cancer 50 (2014) 1799–1807Our work shows that integrated 2D/3D- mammogra-
phy signiﬁcantly improves cancer detection and
screen-reading sensitivity for single-reading and for
double-reading strategies, yielding an incremental
CDR of 2.7/1000 screens attributable to integrating
3D with 2D-mammography, relative to 2D-mammogra-
phy alone. Our initial report of STORM [4], based on
double-reading, did not include follow-up for interval
cancers, hence the current analyses also allow estimation
of comparative sensitivity at 1-year follow-up (Table 5).
It is clear from the cancer detection measures we report
(Tables 1, 2 and 5) that strategies using integrated 2D/
3D-mammography will have the largest eﬀect in terms
of detecting cancers, although double-reading is also
associated with further incremental detection – an addi-
tional four cancers representing an incremental CDR of
0.55/1000, relative to single-reading, whether 2D-
mammography or 2D/3D-mammography is used.
Historically, many population-based breast screening
programs adopted double-reading because it improves
cancer detection, an estimated 5–15% [18–20] increase
in the proportion of screen-detected cancers relative to
single-reading. Our study also conﬁrms the eﬀect of dou-
ble-reading (which detected an additional 6.7% of
screen-detected cancers in our data), so although dou-
ble-reading had a relatively modest detection eﬀect, this
was not negated by using 2D/3D-mammography.
Because roughly half of FPRs in STORM were
recalled at 2D-mammography and also at 2D/3D-mam-
mography (applying single or double-reading), and since
more FPR resulted exclusively from 2D-mammography
compared with 2D/3D-mammography, then 2D/3D-
mammography screening will potentially reduce FPR
only if recall is conditional to 2D/3D-mammography
positivity (Tables 3–5). Integrated 2D/3D-mammographwith conditional recall (whereby screens recalled at 2D-
mammography only would not be recalled) yielded the
most eﬀective FP:TP ratios (Table 5). In the STORM
study, participants were recalled to assessment if
recalled by either reader hence we were unable to
investigate the eﬀect of double-reading strategies that
use arbitration between readers.
At present, the majority of population-based
screening programs use conventional 2D-mammogra-
phy with double-reading, however there is considerable
variability in screening practice and many settings use
2D-mammography with single-reading. It is therefore
noteworthy that based on our data, these are relatively
less sensitive screening strategies, and result in more
FPR, relative to 2D/3D-mammography strategies as
shown in Table 5. Therefore, it seems timely to rethink
breast screening strategies and to consider how best to
further evaluate the integration of 3D-mammography
in screening practice. Given that double-reading is
resource-intensive, and that integrated 2D/3D-mam-
mography is also resource-intensive (approximate dou-
bling of screen-reading time but expected to decrease
with experience [8,21]), we examined estimates for sin-
gle-reading of integrated 2D/3D-mammography – we
estimated that this strategy would detect more cancers,
and would result in less FPR (Tables 2 and 5) than
the frequently practiced strategy of double-reading of
2D-mammography. We are unable to discuss our ﬁnd-
ings on comparative analyses of breast screening strate-
gies relative to those of other studies because to the best
of our knowledge (based on a literature search [4]; see
Section 5) there are no published studies addressing
the same issue we address in this study. It could be
argued that our reported sensitivity of 60% for double-
reading of 2D-mammography is low however this
Table 5
Breast screening strategies ranked by false:true positive (FP:TP) ratioA and corresponding recall rate and sensitivity.








(95% CI), n = 65 cancers
Integrated 2D/3D-mammography, single-reading
(conditionalC recall)
204:55 3.7 (2.7, 5.1) 3.6% (3.1, 4.0) 85% (74, 92)
Integrated 2D/3D-mammography, double-reading
(conditionalC recall)
253:59 4.3 (3.2, 5.7) 4.3% (3.8, 4.8) 91% (81, 97)
Integrated 2D/3D-mammography, single-reading
(recall if either 2D or 2D/3D positive)
328:55 6.0 (4.5, 8.1) 5.3% (4.8, 5.8) 85% (74, 92)
Integrated 2D/3D-mammography, double-reading
(recall if either 2D or 2D/3D positive)
394:59 6.7 (5.1, 8.9) 6.2% (5.7, 6.8) 91% (81, 97)
2D-mammography, single-reading 272:35 7.8 (5.45, 11.4) 4.2% (3.8, 4.7) 54% (41, 66)
2D-mammography, double-readingD 321:39 8.2 (5.9, 11.8) 4.9% (4.5, 5.5) 60% (47, 72)
A FP:TP ratio represents the number of FP recalls for each screen-detected breast cancer, hence screening strategies have been ranked from the
lowest to highest FP:TP ratio (indicating the most to least eﬀective FP to TP trade-oﬀ).
B Denominator for analysis of recall rates was 7293 (from 7292 screens, two bilateral cancers were double-counted (see Section 3) and one false-
negative assessment was excluded from analysis).
C Conditional false positive recall (FPR) estimates the FPR using integrated 2D/3D-mammography positivity as a condition to recall (meaning
that screens recalled at 2D-mammography only would not be recalled).
D Double-reading resulted in recall if recalled by either reader (the screening with tomosynthesis or standard mammography (STORM) study did
not use arbitration or third reading for discordant reads, therefore these strategies are not included in the above analyses).
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grated 2D/3D-mammography screening. If this sensitiv-
ity proportion is recalculated including the interval
cancers but ignoring the additional cancers found only
through integrating 3D-mammography in screen-read-
ing, the sensitivity of double-reading of 2D-mammogra-
phy would approximate 86% which would accord with
that expected at 1-year follow-up. So, our estimated sen-
sitivity for double-reading of 2D-mammography
appears low in comparison to that achieved with 2D/
3D-mammography screening. Our comparative data
can also be used to inform cost-eﬀectiveness studies of
the various screening strategies.
We present comparative analyses of mammography
screening strategies to stimulate rethinking of popula-
tion screening practice and to encourage trials that
investigate new mammography strategies, and not to
suggest prompt changes to established standards in
breast screening. We are cognisant that our study has
limitations, as detailed in our ﬁrst report of STORM
[4] – the sequential screen-reading may have over-esti-
mated detection from 2D/3D-mammography, although
the interim Oslo report [5] similarly showed incremental
cancer detection from 2D/3D-mammography. We rec-
ommend that our ﬁndings be used to inform and sup-
port the planning of breast screening evaluations and
trials. Ideally, these would be randomised controlled tri-
als (RCTs) to allow assessment of initial outcomes
(detection measures), as well as impact on interval can-
cer rates to elucidate whether or not the additional
detection from 2D/3D-mammography is likely to confer
incremental screening beneﬁt [22]. Screening beneﬁt
cannot be assumed on the basis of additional cancerdetection alone because of the possibility that increased
cancer detection from 3D-mammography technology
may represent over-detection [22]. However, if it could
be shown that integrated 2D/3D-mammography would
also lead to a reduction in interval cancer rates (relative
to 2D-mammography strategies) then this would indi-
cate that 3D-mammography has the capability of
early-detecting biologically relevant cancers (thus
averting future interval cancers). The impact of 2D/
3D-mammography on interval cancer rates cannot be
deduced from our study because all women had 2D/
3D-mammography screening, therefore the observed
ﬁrst-year interval cancers were not detected at either
2D-mammography or 2D/3D-mammography. RCTs
would be the most valid design to investigate this issue
but would require a very large sample size to be powered
for measurement of diﬀerences in interval cancer rates,
and would require collaboration between programs, as
well as timely linkage to cancer registries to identify
interval cancers. We caution against over-interpretation
of (or extrapolation from) our estimated ﬁrst-year inter-
val cancer rate given the uncertainty around this esti-
mate (reﬂected in the wide conﬁdence interval), and we
suggest that comparison of interval cancer rates using
historical or geographical controls be avoided because
such approaches may not adequately account for diﬀer-
ences in underlying cancer rates.
Because STORM [4] was the ﬁrst-ever screening
round with 2D/3D mammography of participating
women, the increased cancer detection in repeat
screening of the same population using 2D/3D-mam-
mography has not been quantiﬁed, and this should
also be considered when interpreting our ﬁndings.
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mate over-detection [1,23] nor powered for comparison
of the characteristics of cancers detected only at 2D/
3D-mammography relative to those detected at 2D-
mammography. However, given the substantial
increase in CDR from 2D/3D-mammography both
these issues merit evaluation in future research that
builds knowledge beyond the ‘ﬁrst in population
screening’ prospective trials [4,5] of 2D/3D-mammog-
raphy screening. It is also noteworthy that the
STORM trial was conducted in Trento and Verona
screening services, and in Italy, as for other European
countries, breast cancer is the leading cancer site in
women [24]. Ferlay et al. [24] recently reported that
age-standardised breast cancer incidence rates varied
substantially between European countries (49–148 per
100,000) and that Italy had a breast cancer incidence
rate of 118/100,000 at the relatively higher end of
the estimated incidence rate range for European
women.
The average glandular radiation dose from the multi-
ple low-dose projections obtained during a single acqui-
sition of 3D-mammography has been reported to
approximate that from 2D-mammography [8,25–27].
However, using integrated 2D/3D-mammography
entails both 2D and 3D-acquisitions at the same screen-
ing episode, which roughly doubles the radiation dose to
the breast. To avoid the problem of increased radiation,
integrated 2D/3D-mammography for population
screening should be further evaluated using options that
eliminate dual acquisitions, such as methods that recon-
struct the 2D-images from the tomosynthesis acquisition
as shown by Skaane et al. [28], or by potentially using
3D-mammography only as being done in the Malmo
trial [29].
Our work presents comparative detection measures
for various mammography screening strategies, high-
lighting that currently practiced screening strategies
may not be the most eﬀective way of implementing pop-
ulation breast screening in the future, and underscores
the need to revisit this issue. We recommend that our
ﬁndings be used as an evidence framework to identify
and investigate through formal evaluations (preferably
RCTs) breast screening strategies that include 3D-mam-
mography with an emphasis on examining initial end-
points (detection measures) and surrogate end-points
(interval cancer rates) that will inform us about the
potential of these new screening strategies to enhance
cancer control eﬀorts. Although a reduction in interval
cancer rates can only be regarded as a surrogate measure
of screening eﬃcacy, if it can be demonstrated for 2D/
3D-mammography, it would allow inferences about its
capability to detect clinically relevant breast cancers, in
the absence of which over-detection may be a genuine
concern.5. Panel: Research in context
5.1. Literature review:
NH searched the English language published work
up to December 2013, to assess the evidence on com-
parisons of breast screening strategies that include
digital breast tomosynthesis (3D mammography) using
the search strategy and eligibility criteria detailed in a
published systematic review [8]. The search consisted
of a Medline search (exploded ‘breast neoplasm’,
combined with ‘tomosyn$’ in title) and also contact
with experts. This search did not identify any studies
reporting on population breast screening (inclusive of
tomosynthesis/3D mammography) that compared
detection measures for screening strategies comprising
single-reading or double-reading using standard 2D-
mammography or 2D/3D-mammography.5.2. Interpretation:
To the best of our knowledge, we report the ﬁrst
evidence on comparative detection measures for vari-
ous mammography screening strategies (2D-mam-
mography or 2D/3D-mammography, applying single-
reading or double-reading), that also factor the trade-
oﬀ between true-positive and false-positive detection.
Our ﬁndings highlight that current breast screening
strategies (2D-mammography with single or double-
reading) may not represent the most eﬀective strategies
and underscore the need to revisit this issue by evalu-
ating strategies that integrate 3D-mammography, to
inform future breast screening practice.Author contributions
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